Key result
Combination therapy with imatinib, bevacizumab, S-1, and cisplatin led to dramatic clinical improvement and reduction in right ventricular systolic pressure in a patient with pulmonary tumor thrombotic microangiopathy.
Why the study?
Does combination therapy with imatinib, bevacizumab, and chemotherapy improve symptoms and hemodynamics in a patient with pulmonary tumor thrombotic microangiopathy?
Case Report (n=1)
Does combination therapy with imatinib, bevacizumab, and chemotherapy improve symptoms and hemodynamics in a patient with pulmonary tumor thrombotic microangiopathy?
Combination therapy with molecular-targeted drugs (imatinib and bevacizumab) and chemotherapy may be an effective treatment strategy for patients with antemortem diagnosis of pulmonary tumor thrombotic microangiopathy.
May suggest targeted therapy for antemortem pulmonary tumor thrombotic microangiopathy; hypothesis-generating and requires prospective validation.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal cancer-related complication with rapid progression. Although the underlying molecular mechanisms of PTTM remain unclear, platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) may play important roles in the pathogenesis of PTTM. We herein report a case of PTTM that was diagnosed antemortem by pathology using pulmonary wedge aspiration. The patient was treated with a combination therapy of imatinib (PDGF receptor antagonist), bevacizumab (VEGF receptor inhibitor), S-1, and cisplatin. These findings suggest that molecular-target drugs are effective for the treatment of PTTM.
No takes yet. Share an insight, caveat, or question.
Higo et al. (2014) conducted a case report in Pulmonary tumor thrombotic microangiopathy (PTTM) (n=1). Combination therapy of imatinib, bevacizumab, S-1, and cisplatin was evaluated on Clinical and hemodynamic improvement. Combination therapy with imatinib, bevacizumab, S-1, and cisplatin led to dramatic clinical improvement and reduction in right ventricular systolic pressure in a patient with pulmonary tumor thrombotic microangiopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: